⌘K
Loading ticker…
As of 2026-08-24, C4 Therapeutics, Inc. (CCCC) has a 3-month relative strength percentile of 75 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 64. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.0%, relative volume 0.70×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CCCC is in a stage 2 uptrend, week 2. Currently in a 38-day base; basing ADR 7.1% (broad 8.9%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 4.1% / 37.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CCCC is held by 6 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $2M notional. Top 3 carry $2M.
Held by 16 ETFs · $16M across latest filings · largest weight 0.66% (QQQS).
Top 6 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| AVSC | 0.02% | $503K | — |
| QQQS | 0.66% | $124K | +0.19 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $118K | — |
| IBBQ | 0.03% | $22K | +0.01 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.02% |
| $16K |
| — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CCCC Jan avg: 9.32% median: 4.43% win: 50% σ: 16.13% n: 4 2022-04-12 → 2026-07-31 | CCCC Feb avg: 16.38% median: 10.10% win: 50% σ: 52.47% n: 4 2022-04-12 → 2026-07-31 | CCCC Mar avg: -27.39% median: -33.01% win: 0% σ: 18.00% n: 4 2022-04-12 → 2026-07-31 | CCCC Apr avg: -1.92% median: 2.50% win: 60% σ: 12.58% n: 5 2022-04-12 → 2026-07-31 | CCCC May avg: 1.39% median: -15.29% win: 40% σ: 32.89% n: 5 2022-04-12 → 2026-07-31 | CCCC Jun avg: -0.27% median: 3.86% win: 60% σ: 13.07% n: 5 2022-04-12 → 2026-07-31 | CCCC Jul avg: 26.44% median: 41.45% win: 80% σ: 29.81% n: 5 2022-04-12 → 2026-07-31 | CCCC Aug avg: 0.07% median: -0.55% win: 50% σ: 21.76% n: 4 2022-04-12 → 2026-07-31 (current) | CCCC Sep avg: -18.32% median: -13.81% win: 0% σ: 11.86% n: 4 2022-04-12 → 2026-07-31 | CCCC Oct avg: 0.22% median: 1.60% win: 50% σ: 16.73% n: 4 2022-04-12 → 2026-07-31 | CCCC Nov avg: -3.08% median: -3.54% win: 50% σ: 11.52% n: 4 2022-04-12 → 2026-07-31 | CCCC Dec avg: 41.27% median: -25.20% win: 25% σ: 136.98% n: 4 2022-04-12 → 2026-07-31 |